AR086191A1 - Triazolopiridinas - Google Patents
TriazolopiridinasInfo
- Publication number
- AR086191A1 AR086191A1 ARP120101355A ARP120101355A AR086191A1 AR 086191 A1 AR086191 A1 AR 086191A1 AR P120101355 A ARP120101355 A AR P120101355A AR P120101355 A ARP120101355 A AR P120101355A AR 086191 A1 AR086191 A1 AR 086191A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkoxy
- halo
- nr8r7
- group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Métodos para preparar dichos compuestos. Composiciones y combinaciones farmacéuticas que comprenden dichos compuestos. Uso de dichos compuestos para preparar una composición farmacéutica para el tratamiento o la profilaxis de una enfermedad. Compuestos intermediarios útiles para preparar dichos compuestos antiproliferativos.Reivindicación 1: Un compuesto de fórmula general (1), en donde: R1 representa un grupo fenilo o piridilo, que está sustituido, una o más veces, en forma idéntica o diferente, con un sustituyente seleccionado entre: R6-(alcoxi C1-6), R6-O-, -C(=O)R6, -C(=O)O-R6, -N(H)C(=O)R6, -N(H)C(=O)NR6R7, -NR6R7, -C(=O)N(H)R6, -C(=O)NR6R7, R6-S-, R6-S(=O)2-, -N(H)S(=O)2R6, -S(=O)2N(H)R6; y que está opcionalmente sustituido, una o más veces, en forma idéntica o diferente, con un sustituyente seleccionado entre: halo, hidroxi, nitro, alquilo C1-6, alcoxi C1-6, hidroxi-alquilo C1-6, -N(H)C(=O)R8, -N(H)C(=O)NR8R7, -C(=O)N(H)R8, -N(H)S(=O)2R8; R2 representa un grupo de fórmula (2); donde * indica el punto de unión de dicho grupo con el resto de la molécula; Q1 representa un grupo seleccionado entre: N, CH, C(alquilo C1-6), C-(alcoxi C1-6), C-halo; Q2 representa un grupo seleccionado entre: N, CH, CR5b; Q3 representa un grupo seleccionado entre: N, CH, CR5b; R5a representa un grupo seleccionado entre: halo, nitro, alquilo C1-6, halo-alquilo C1-6, alcoxi C1-6, halo-alcoxi C1-6, hidroxi-alquilo C1-6, alcoxi C1-6-alquilo C1-6, halo-alcoxi C1-6-alquilo C1-6, R8-(alcoxi C1-6), R8-O-, -NR8R7, R8-S-, R8-S(=O), R8-S(=O)2-, (cicloalquil C3-6)-(CH2)n-O-; R5b representa un grupo seleccionado entre: halo, hidroxi, ciano, nitro, alquilo C1-6, halo-alquilo C1-6, alcoxi C1-6, halo-alcoxi C1-6, hidroxi-alquilo C1-6, alcoxi C1-6-alquilo C1-6, halo-alcoxi C1-6-alquilo C1-6, R8-(alquilo C1-6), R8-(CH2)n(CHOH)(CH2)m-, R8-(alcoxi C1-6), R8-(CH2)n(CHOH)(CH2)p-O-, R8-(alcoxi C1-6-alquilo C1-6), R8-(alcoxi C1-6-alquil C1-6)-O-, -O-(CH2)n-C(=O)NR8R7, R8-O-, -C(=O)R8, -C(=O)O-R8, -OC(=O)-R8, -N(H)C(=O)R8, -N(R7)C(=O)R8, -N(H)C(=O)NR8R7, -N(R7)C(=O)NR8R7, -NR8R7, -NR7R7, -C(=O)N(H)R8, -C(=O)NR8R7, R8-S-, R8-S(=O), R8-S(=O)2-, -N(H)S(=O)R8, -N(R7)S(=O)R8, -S(=O)N(H)R8, -S(=O)NR8R7, -N(H)S(=O)2R8, -N(R7)S(=O)2R8, -S(=O)2N(H)R8, -S(=O)2NR8R7, -S(=O)(=NR8)R7, -S(=O)(=NR7)R8, -N=S(=O)(R8)R7; R3 representa un átomo de hidrógeno, un átomo de halógeno, un grupo hidroxi, amino-, ciano, nitro, alquilo C1-4, halo-alquilo C1-4, alcoxi C1-4, halo-alcoxi C1-4, hidroxi-alquilo C1-4, alcoxi C1-4-alquilo C1-4, halo-alcoxi C1-4-alquilo C1-4, alquenilo C2-6, alquinilo C2-6, halo-alquenilo C2-6, halo-alquinilo C2-6, cicloalquilo C3-6, o halo-cicloalquilo C3-6; R4 representa un átomo de hidrógeno, un átomo de halógeno, un grupo hidroxi, amino-, ciano, nitro, alquilo C1-4, halo-alquilo C1-4, alcoxi C1-4, halo-alcoxi C1-4, hidroxi-alquilo C1-4, alcoxi C1-4-alquilo C1-4, halo-alcoxi C1-4-alquilo C1-4, alquenilo C2-6, alquinilo C2-6, halo-alquenilo C2-6, halo-alquinilo C2-6, cicloalquilo C3-6, o halo-cicloalquilo C3-6; R5 representa un átomo de hidrógeno; R6 representa un grupo seleccionado entre cicloalquilo C3-6, heterociclilo, arilo, heteroarilo, -(CH2)q-(cicloalquilo C3-6), -(CH2)q-(heterociclilo de entre 3 y 10 miembros), -(CH2)q-arilo, o -(CH2)q-heteroarilo de entre 3 y 10 miembros, donde dicho grupo está opcionalmente sustituido, una o más veces, en forma idéntica o diferente, con un sustituyente seleccionado entre: halo, hidroxi, ciano, nitro, alquilo C1-6, halo-alquilo C1-6, alcoxi C1-6, halo-alcoxi C1-6, hidroxi-alquilo C1-6, alcoxi C1-6-alquilo C1-6, halo-alcoxi C1-6-alquilo C1-6, R8-(alquilo C1-6), R8-(CH2)n(CHOH)(CH2)m-, R8-(alcoxi C1-6), R8-(CH2)n(CHOH)(CH2)p-O-, R8-(alcoxi C1-6-alquilo C1-6), R8-(alcoxi C1-6-alquil C1-6)-O-, arilo, R8-O-, -C(=O)R8, -C(=O)O-R8, -OC(=O)-R8, -N(H)C(=O)R8, -N(R7)C(=O)R8, -N(H)C(=O)NR8R7, -N(R7)C(=O)NR8R7, -NR8R7, -C(=O)N(H)R8, C(=O)NR8R7, R8-S-, R8-S(=O), R8-S(=O)2-, -N(H)S(=O)R8, -N(R7)S(=O)R8, -S(=O)N(H)R8, -S(=O)NR8R7, -N(H)S(=O)2R8, -N(R7)S(=O)2R8, -S(=O)2N(H)R8, -S(=O)2NR8R7, -S(=O)(=NR8)R7, -S(=O)(=NR7)R8, -N=S(=O)(R8)R7; R7 representa un átomo de hidrógeno, un grupo alquilo C1-6 o un grupo cicloalquilo C3-6; R8 representa un átomo de hidrógeno o un grupo alquilo C1-6 o cicloalquilo C3-6, donde dicho grupo alquilo C1-6 o cicloalquilo C3-6 está opcionalmente sustituido, una o más veces, en forma idéntica o diferente, con un sustituyente seleccionado entre: halo, hidroxi, -NHR7, -NR7R7, -N(alquil C1-3)-C(=O)R7, -N(alquil C1-3)-C(=O)OR7, alquilo C1-3, R7-S(=O)2-, alcoxi C1-3, halo-alcoxi C1-3; n, m, p, representan, en forma independiente entre sí, el entero 0, 1, 2 ó 3; y q representa el entero 0, 1, 2 ó 3; o un estereoisómero, un tautómero, un N-óxido, un hidrato, un solvato o una sal del mismo, o una mezcla de los mismos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11163342 | 2011-04-21 | ||
| EP11167872 | 2011-05-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR086191A1 true AR086191A1 (es) | 2013-11-27 |
Family
ID=46124297
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120101355A AR086191A1 (es) | 2011-04-21 | 2012-04-20 | Triazolopiridinas |
Country Status (39)
| Country | Link |
|---|---|
| US (1) | US20140120087A1 (es) |
| EP (1) | EP2699575B1 (es) |
| JP (1) | JP5989091B2 (es) |
| KR (1) | KR20140025470A (es) |
| CN (1) | CN103608350B (es) |
| AP (1) | AP3491A (es) |
| AR (1) | AR086191A1 (es) |
| AU (1) | AU2012244859B2 (es) |
| CA (1) | CA2833657A1 (es) |
| CL (1) | CL2013003044A1 (es) |
| CO (1) | CO6801751A2 (es) |
| CR (1) | CR20130539A (es) |
| CY (1) | CY1116439T1 (es) |
| DK (1) | DK2699575T3 (es) |
| DO (1) | DOP2013000244A (es) |
| EA (1) | EA023766B1 (es) |
| EC (1) | ECSP13013011A (es) |
| ES (1) | ES2539265T3 (es) |
| GT (1) | GT201300254A (es) |
| HR (1) | HRP20150517T1 (es) |
| HU (1) | HUE025496T2 (es) |
| IL (1) | IL228704A0 (es) |
| JO (1) | JO3040B1 (es) |
| MA (1) | MA35049B1 (es) |
| ME (1) | ME02143B (es) |
| MX (1) | MX348783B (es) |
| MY (1) | MY164939A (es) |
| PE (1) | PE20141351A1 (es) |
| PH (1) | PH12013502169A1 (es) |
| PL (1) | PL2699575T3 (es) |
| PT (1) | PT2699575E (es) |
| RS (1) | RS54044B1 (es) |
| SA (1) | SA112330466B1 (es) |
| SG (1) | SG194003A1 (es) |
| SI (1) | SI2699575T1 (es) |
| TW (1) | TWI558703B (es) |
| UY (1) | UY34034A (es) |
| WO (1) | WO2012143329A1 (es) |
| ZA (1) | ZA201308707B (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9006229B2 (en) | 2011-04-21 | 2015-04-14 | Gilead Sciences, Inc. | Benzothiazole compounds and their pharmaceutical use |
| UA112096C2 (uk) * | 2011-12-12 | 2016-07-25 | Байєр Інтеллектуал Проперті Гмбх | Заміщені триазолопіридини та їх застосування як інгібіторів ttk |
| WO2013103738A1 (en) | 2012-01-04 | 2013-07-11 | Gilead Sciences, Inc. | Napthalene acetic acid derivatives against hiv infection |
| US9376392B2 (en) | 2012-01-04 | 2016-06-28 | Gilead Sciences, Inc. | 2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS |
| CN104284896B (zh) | 2012-03-14 | 2016-06-01 | 拜耳知识产权有限责任公司 | 取代的咪唑并哒嗪 |
| JP6238979B2 (ja) * | 2012-07-10 | 2017-11-29 | バイエル・ファルマ・アクティエンゲゼルシャフト | 置換トリアゾロピリジンを調製する方法 |
| WO2014020043A1 (en) | 2012-08-02 | 2014-02-06 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer |
| WO2014020041A1 (en) | 2012-08-02 | 2014-02-06 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer |
| WO2014195276A1 (en) * | 2013-06-07 | 2014-12-11 | Bayer Pharma Aktiengesellschaft | Substituted triazolopyridines having activity as mps-1 inhibitors |
| EP3004092B1 (en) * | 2013-06-07 | 2017-03-22 | Bayer Pharma Aktiengesellschaft | Substituted triazolopyridines |
| JP2016521737A (ja) * | 2013-06-10 | 2016-07-25 | バイエル・ファルマ・アクティエンゲゼルシャフト | 癌を治療するための新規な化合物 |
| MA38656A1 (fr) * | 2013-06-11 | 2018-05-31 | Bayer Pharma AG | Combinaisons pour le traitement du cancer comprenant un inhibiteur de la kinase mps-1 et un inhibiteur de la mitose |
| AP2015008898A0 (en) | 2013-06-11 | 2015-12-31 | Bayer Pharma AG | Prodrug derivatives of substituted triazolopyridines |
| EP2860177A3 (en) | 2013-09-20 | 2015-06-10 | Bayer Intellectual Property GmbH | Synthesis of functionalized arenes |
| HUE064630T2 (hu) | 2015-04-17 | 2024-04-28 | Crossfire Oncology Holding B V | Prognosztikai biomarkerek TTK-inhibitoros kemoterápiához |
| MX393395B (es) * | 2017-03-16 | 2025-03-24 | Jiangsu Hengrui Medicine Co | Derivado de heteroaril[4,3-c]pirimidina-5-amina, método de preparación del mismo y usos médicos del mismo. |
| US20230086702A1 (en) | 2019-04-18 | 2023-03-23 | The Johns Hopkins University | Substituted 2-amino-pyrazolyl-[1,2,4]triazolo[1,5a]pyridine derivatives and use thereof |
| CN114302878A (zh) | 2019-07-03 | 2022-04-08 | 大日本住友制药肿瘤公司 | 酪氨酸激酶非受体1(tnk1)抑制剂及其用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| ES2315909T3 (es) | 2004-08-17 | 2009-04-01 | GALDERMA RESEARCH & DEVELOPMENT | Nuevos compuestos bioaromaticos que son activadores de los receptores del tipo ppar y su utilizacion en composiciones cosmeticas y farmaceuticas. |
| BRPI0716239A2 (pt) | 2006-08-30 | 2013-08-13 | Cellzome Ltd | derivados de triazol como inibidores de cinase |
| EP2178868A1 (en) * | 2007-07-18 | 2010-04-28 | Novartis Ag | Bicyclic heteroaryl compounds and their use as kinase inhibitors |
| NZ584138A (en) | 2007-08-23 | 2011-10-28 | Astrazeneca Ab | 2-anilinopurin-8-ones as inhibitors of ttk/mps1 for the treatment of proliferative disorders |
| MX2010002312A (es) * | 2007-08-31 | 2010-03-18 | Merck Serono Sa | Compuestos de triazolopiridina y su uso como inhibidores de cinasa reguladora de señal de apoptosis. |
| GB0719803D0 (en) | 2007-10-10 | 2007-11-21 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| JP2011504900A (ja) * | 2007-11-27 | 2011-02-17 | セルゾーム リミティッド | Ｐｉ３ｋ阻害剤としてのアミノトリアゾール |
| WO2010092041A1 (en) * | 2009-02-13 | 2010-08-19 | Fovea Pharmaceuticals Sa | [1, 2, 4] triazolo [1, 5 -a] pyridines as kinase inhibitors |
| CA2760077A1 (en) | 2009-04-29 | 2010-11-04 | Marcus Koppitz | Substituted imidazoquinoxalines |
| CN102596932A (zh) | 2009-09-04 | 2012-07-18 | 拜耳医药股份有限公司 | 作为酪氨酸苏氨酸激酶抑制剂的取代氨基喹喔啉 |
| EP2343297A1 (en) * | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Triazolopyridines |
| UY33452A (es) * | 2010-06-16 | 2012-01-31 | Bayer Schering Pharma Ag | Triazolopiridinas sustituidas |
-
2012
- 2012-04-16 EA EA201301181A patent/EA023766B1/ru not_active IP Right Cessation
- 2012-04-16 DK DK12721779.2T patent/DK2699575T3/da active
- 2012-04-16 MA MA36344A patent/MA35049B1/fr unknown
- 2012-04-16 RS RS20150345A patent/RS54044B1/sr unknown
- 2012-04-16 ME MEP-2015-80A patent/ME02143B/me unknown
- 2012-04-16 SI SI201230220T patent/SI2699575T1/sl unknown
- 2012-04-16 AP AP2013007182A patent/AP3491A/xx active
- 2012-04-16 WO PCT/EP2012/056914 patent/WO2012143329A1/en not_active Ceased
- 2012-04-16 PT PT127217792T patent/PT2699575E/pt unknown
- 2012-04-16 PL PL12721779T patent/PL2699575T3/pl unknown
- 2012-04-16 JP JP2014505584A patent/JP5989091B2/ja not_active Expired - Fee Related
- 2012-04-16 US US14/113,017 patent/US20140120087A1/en not_active Abandoned
- 2012-04-16 ES ES12721779.2T patent/ES2539265T3/es active Active
- 2012-04-16 SG SG2013073044A patent/SG194003A1/en unknown
- 2012-04-16 MX MX2013012289A patent/MX348783B/es active IP Right Grant
- 2012-04-16 MY MYPI2013701964A patent/MY164939A/en unknown
- 2012-04-16 PH PH1/2013/502169A patent/PH12013502169A1/en unknown
- 2012-04-16 CA CA2833657A patent/CA2833657A1/en not_active Abandoned
- 2012-04-16 PE PE2013002378A patent/PE20141351A1/es not_active Application Discontinuation
- 2012-04-16 CN CN201280030682.XA patent/CN103608350B/zh not_active Expired - Fee Related
- 2012-04-16 AU AU2012244859A patent/AU2012244859B2/en not_active Ceased
- 2012-04-16 EP EP12721779.2A patent/EP2699575B1/en active Active
- 2012-04-16 KR KR1020137030546A patent/KR20140025470A/ko not_active Ceased
- 2012-04-16 HU HUE12721779A patent/HUE025496T2/en unknown
- 2012-04-16 HR HRP20150517TT patent/HRP20150517T1/hr unknown
- 2012-04-18 SA SA112330466A patent/SA112330466B1/ar unknown
- 2012-04-18 JO JOP/2012/0093A patent/JO3040B1/ar active
- 2012-04-20 TW TW101114259A patent/TWI558703B/zh not_active IP Right Cessation
- 2012-04-20 UY UY0001034034A patent/UY34034A/es not_active Application Discontinuation
- 2012-04-20 AR ARP120101355A patent/AR086191A1/es unknown
-
2013
- 2013-10-03 IL IL228704A patent/IL228704A0/en unknown
- 2013-10-18 GT GT201300254A patent/GT201300254A/es unknown
- 2013-10-21 DO DO2013000244A patent/DOP2013000244A/es unknown
- 2013-10-21 CO CO13248763A patent/CO6801751A2/es active IP Right Grant
- 2013-10-21 CL CL2013003044A patent/CL2013003044A1/es unknown
- 2013-10-21 CR CR20130539A patent/CR20130539A/es unknown
- 2013-11-05 EC ECSP13013011 patent/ECSP13013011A/es unknown
- 2013-11-20 ZA ZA2013/08707A patent/ZA201308707B/en unknown
-
2015
- 2015-06-12 CY CY20151100512T patent/CY1116439T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR086191A1 (es) | Triazolopiridinas | |
| AR079166A1 (es) | Triazolopiridinas | |
| AR088029A1 (es) | Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central | |
| AR112797A1 (es) | Inhibidores de kras g12c y métodos para utilizarlos | |
| AR078888A1 (es) | Derivados heterociclicos nitrogenados de bencimidazol-imidazol utiles para tratar infecciones por hvc y composiciones farmaceuticas que los comprenden. | |
| AR076435A1 (es) | Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos | |
| AR089143A1 (es) | Triazolopiridinas sustituidas con actividad inhibidora de ttk | |
| AR090220A1 (es) | Inhibidores de serina/treonina cinasa | |
| AR091023A1 (es) | Inhibidores del nampt | |
| AR086357A1 (es) | Derivados de indazol sustituidos activos como inhibidores de quinasas | |
| AR036365A1 (es) | 1,8-naftiridin-4(1h)-onas alquin-aril sustituidas y composiciones farmaceuticas que las contienen | |
| AR081934A1 (es) | Compuestos de triazolopiridinas sustituidas, una combinacion farmaceutica que los comprende y el uso de dichos compuestos en la preparacion de medicamentos | |
| AR093740A1 (es) | Amidas como inhibidores de pim | |
| AR091093A1 (es) | Tienopirimidinas | |
| RU2014140735A (ru) | ПРОИЗВОДНЫЕ ПИРАЗОЛО[1, 5-a]ПИРИМИДИНА, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ СОЕДИНЕНИЯ, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| AR088423A1 (es) | Ligadores p1 ciclicos como inhibidores del factor xia | |
| CO6331437A2 (es) | Compuestos de pirrolo[2,3-d]pirimidina | |
| AR086546A1 (es) | Derivados de 7h-purin-8(9h)-ona como inhibidores de jak | |
| AR101106A1 (es) | Inhibidores de tirosina quinasa de bruton | |
| AR075253A1 (es) | Pirimidinas fusionadas, procesos de preparacion y composiciones farmaceuticas que los contiene. | |
| PE20151860A1 (es) | Derivados de 6-(5-hidroxi-1h-pirazol-1-il)nicotinamida y su uso como inhidores de la phd | |
| RU2015121431A (ru) | Замещенные производные индол-5-ола и их терапевтическое применение | |
| AR091022A1 (es) | Inhibidores del nampt | |
| AR100810A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR100806A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |